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Summary Many studies have suggested that inﬂammation may participate in the
pathogenesis of non-valvular atrial ﬁbrillation (AF). However, it has been unknown
by exposure to what the inﬂammation is caused. Recently, we reported that Toll-
like receptor 2 (TLR2) level on monocytes was signiﬁcantly up-regulated in viral
and bacterial infections, but not in non-infectious inﬂammatory states. Our purpose
was to test the hypothesis that expression of TLR2 levels may be up-regulated in
patients with non-valvular AF. A total of 48 consecutive patients with non-valvular
AF who were hospitalized for catheter ablation were enrolled in this study. TLR2
levels were assayed by using ﬂow-cytometric analysis and compared with volunteers
in sinus rhythm (control group, n = 24). Additionally, C-reactive protein (CRP) and
interleukin-6 (IL-6) levels were assayed, and the left atrial volume indexes (LAVI)
in the non-valvular AF group were measured. The results demonstrated that TLR2
levels in the non-valvular AF group were signiﬁcantly higher than in the control
group (median, 4682 vs. 3866 sites/cell; P < 0.01). Moreover, non-valvular AF patients
had signiﬁcantly higher IL-6 levels than controls. However, there was no signiﬁcant
difference in CRP levels between the two groups. It was observed in 44 AF patients, in
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whom pulmonary vein isolation was conﬁrmed to be successful, that the LAVI signif-
icantly diminished 1 month after ablation (median, 33.6 vs. 29.5ml/m2; P < 0.001),
but not the TLR2 and IL-6 levels. Our results implied that an infectious inﬂammation
may participate in the pathogenesis of non-valvular AF.
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Introduction
Atrial ﬁbrillation (AF), the most commonly encoun-
tered arrhythmia in clinical practice, is associated
with substantial morbidity and mortality. AF is gen-
erally categorized into valvular and non-valvular
AF/lone AF, depending on the presence of valvu-
lar heart disease. Atrial biopsies of non-valvular
AF patients provided the evidence that inﬂamma-
tion may participate in the pathogenesis [1], and
the reﬂecting markers in sera have been explored.
In this context, it has been controversial whether
non-valvular AF patients have higher CRP levels
compared with controls in sinus rhythm [2—7].
On the other hand, Toll-like receptor (TLR) family
members, which are key regulators of both innate
and acquired immune responses, have been stud-
ied not only in the immunological response [8—10],
but also in the clinical implications [11—13]. In
this study, based on our previous ﬁnding that TLR2
expression levels on monocytes are up-regulated
in infectious diseases [14,15], we tested how the
expression level of TLR2 is modulated in patients
with non-valvular AF, compared with volunteers
in sinus rhythm (control group). In addition, we
measured plasma interleukin-6 (IL-6) levels and
amino-terminal propeptide of type III procollagen
(PIIINP) levels in both groups. PIIINP is a collagen III
synthesis marker, and if ﬁbroid degeneration occurs
in the atrium of patients with non-valvular AF, we
hypothesized that it might be reﬂected in PIIINP
levels. Subsequently, we evaluated TLR2 expression
levels and the left atrial volume index (LAVI) before
and 1 month after successful catheter ablation in
the non-valvular AF group.
Methods
Patient population
Forty-eight patients with non-valvular AF, who
underwent catheter ablation for drug-refractory
paroxysmal AF in our hospital, were enrolled. This
group consisted of 39 males and 9 females, rang-
ing from 30 to 72 years old (mean = 54 years).
The patients with non-valvular AF that were indi-
cated for catheter ablation had a left atrial
F
P
i
sCardiology. Published by Elsevier Ireland Ltd. All rights
iameter <45mm. Forty patients were taking med-
cations, including anti-inﬂammatory drugs, such
s angiotensin-converting enzyme inhibitors (ACE-
), angiotensin II receptor blockers (ARB), and
tatins, and eight patients were not taking med-
cation (Table 1). In the non-valvular AF group,
lood samples were taken before and 1 month
fter catheter ablation. In this study, the abla-
ion was deﬁned to be successful with two criteria:
1) patients were free from palpitations during
he ﬁrst month after ablation; (2) the absence
f AF was conﬁrmed by checking the electrocar-
iogram and 24-h Holter monitor a month after
blation. Consequently, 44 out of 48 AF patients
ere judged as successful ablation cases. Alter-
atively, 25 out of 48 AF patients offered blood
amples not only from peripherals but also from
eft atria just before ablation. Volunteers (n = 24)
n sinus rhythm were conﬁrmed to be infection-
ree for at least 1 month at the time of blood
ampling and did not have a fever within a week
rom the time the blood sample was drawn. They
ere categorized as the control group, which con-
isted of 19 males and 5 females, ranging from
0 to 72 years old (mean = 49 years). The control
roup was age- and sex-matched with the non-
alvular AF group. Sixteen out of 24 volunteers were
nder medical treatment for hypertension, hyper-
ipidemia, and diabetes mellitus. Patients were
xcluded with organic disorders responsible for AF,
uch as valvular heart disease, congestive heart
ailure (NYHA class II or greater), recent acute
oronary events/revascularization, thyroid disease,
nd patients with systemic inﬂammatory diseases
ncluding infection, collagen diseases, malignan-
ies, renal failure, and hepatic failure. Informed
onsent was obtained from all patients and vol-
nteers, which was in accordance with a protocol
pproved by the Kagoshima University Ethics Com-
ittee. Ten milliliters of peripheral blood were
aken from each patient with a heparinized bloodlow-cytometer analysis
eripheral blood mononuclear cells (PBMCs) were
solated from heparinized peripheral blood by den-
ity gradient centrifugation using Ficoll-Paque plus
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Table 1 Patient population.
Control (n = 24) Non-valvular AF (n = 48) P-Value
Age (years) 49 54 0.06
Male/female, n (%) 19/5 (79%) 39/9 (81%) 0.72
Hypertension, n (%) 8 (33%) 20 (42%) 0.18
Hyperlipidemia, n (%) 5 (20%) 15 (31%) 0.07
Diabetes mellitus, n (%) 3 (13%) 9 (19%) 0.24
Medication
ACE-I, n (%) 2 (8%) 4 (8%) 1.00
ARB, n (%) 4 (16%) 11 (23%) 0.10
ensin
patie
l
s
o
a
m
S
e
e
o
s
I
m
b
c
s
t
t
p
f
t
v
Q
T
c
t
ﬂ
[
w
a
b
d
w
e
t
o
t
v
c
A
T
S
a
M
I
i
w
S
G
s
t
t
n
U
p
a
i
h
m
m
s
a
p
A
w
t
2
mStatin, n (%) 3 (13%)
ACE-I: angiotensin-converting enzyme inhibitors; ARB: angiot
percentage of male patients, the disease prevalence, and the
iquid (Amersham Bioscience, GE Healthcare, Amer-
ham, UK). To assess the expression levels of TLR2
n monocytes, PBMCs were divided into three tubes
nd stained in parallel with PE-labeled anti-TLR2
onoclonal antibody (mAb) (clone T2.1; eBIO-
CIENCE, CA, USA), anti-CD14 mAb (clone M5E2;
BIOSCIENCE), or control mouse IgG2a (eBM2a;
BIOSCIENCE). The stained cells were analyzed
n a ﬂow cytometer FACS Calibur using CellQuest
oftware (Becton-Dickinson Biosciences, CA, USA).
n this study, we employed a single color ﬂow cyto-
etric analysis to avoid problems of interference
etween ﬂuorescence dyes. For each donor, mono-
ytes were ﬁrst gated according to the forward/side
catter properties and CD14 staining. Subsequently,
he same gate setting for monocytes was applied to
he analysis of TLR2- and control-stained PBMC sam-
les. The mean ﬂuorescence intensity (MFI) value
or just TLR2 was obtained by subtracting the con-
rol staining MFI value from the TLR2 staining MFI
alue.
uantiﬁcation of TLR2 levels
LR2 expression levels on monocyte were numeri-
ally represented as previously described in order
o avoid assay-to-assay variation caused by daily
uctuation in the performance of ﬂow cytometers
14,15]. In this assay system, inter-assay variation
as within acceptable levels (CV < 6.8%). In brief,
mixture of our developed TLR2-coupled standard
eads, which consists of 4 types of beads carrying 4
ifferent numbers of recombinant TLR2 molecules,
as stained in parallel with PBMCs under the same
xperimental conditions in each assay. A calibra-
ion curve was then obtained by plotting MFI values
f the standard beads. Using the calibration curve,
he TLR2 expression level on monocytes was con-
erted to the number of antibody-binding sites per
ell.
R
T
A
i8 (17%) 0.06
II receptor blockers. The number in parentheses shows the
nt ratio taking the medication.
ssessment of left atrial volume index
he LAVI was assessed by echocardiography using
impson’s method [16] before and 1 month after
blation in non-valvular AF patients.
easurement of IL-6 and PIIINP levels
L-6 (pg/ml) was measured by an enzyme
mmunoassay method and PIIINP level (U/ml)
as measured by an immunoradioassay method.
tatistics
iven two data sets, we assessed whether two
amples of observations came from the same dis-
ribution. Since the distributions of all unpaired
wo groups compared in this study were not
ormal and/or homoscedastic, a Mann—Whitney
-test was performed. When we compared the
aired two groups, a paired Student’s t-test or
Wilcoxon signed-rank test was applied accord-
ng to whether the distributions were normal and
omoscedastic or not. Data are expressed as the
ean value± standard deviation (S.D.) or as the
edian value (25—75th percentile) according to the
tatistical processing. Disease prevalence, gender,
nd patients ratio taking medication were com-
ared between the control and the non-valvular
F groups with a chi-square test. All differences
ere considered signiﬁcant at P < 0.05. All statis-
ical analyses were performed with Excel Statistics
006 for Windows® (Social Survey Research Infor-
ation Co., Tokyo, Japan).
esultsLR2 levels in non-valvular AF patients
s shown in Table 1, the number of patients
n the non-valvular AF group with hypertension,
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Figure 1 Comparison between the control group (n = 24) and non-valvular AF group (n = 48). TLR2 levels were compared
between the two groups. Circles represent individual TLR2 expression values (A). CRP levels were compared between
the two groups. Circles represent individual CRP levels (B). WBC values were compared between the two groups. Circles
represent individual WBC values (C). IL-6 levels were compared between the two groups. Circles represent individual
IL-6 levels (D). PIIINP levels were compared between the two groups. Circles represent individual CRP levels (E). Box
plot and the horizontal bar show the interquartile range and median value, respectively. The whiskers extend to at
most 1.5 times the box width (the interquartile range) from either or both ends of the box. P-Value estimates were
based on the Mann—Whitney U-test (A—E).
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Figure 2 Correlation of TLR2 levels with CRP levels/IL-6
levels. The correlation is shown between the TLR2 value
(Y-axis) and the CRP level (X-axis) at the same time point
in each non-valvular AF patient (A). The correlation is
shown between the TLR2 value (Y-axis) and IL-6 level
(X-axis) at the same time point in each non-valvular AF
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yperlipidemia, and diabetes mellitus was 20, 15,
nd 9, respectively. Coronary angiography con-
rmed that no patient had coronary artery disease
≥75% coronary arterial stenosis). The prevalence
f hypertension, hyperlipidemia, and diabetes mel-
itus was similar in the control group (Table 1).
The expression levels of TLR2 in the non-
alvular AF group were signiﬁcantly higher than
n the control group as shown in Fig. 1A
median (25—75th percentile), 4682 (3925—5260)
s. 3866 (3455—4421) sites/cell, P < 0.01]. How-
ver, there was no signiﬁcant difference in CRP
evel and WBC [median (25—75th percentile), 0.08
0.05—0.15) vs. 0.05 (0.05—0.09) mg/dl, P = 0.074
nd 4620 (3793—5390) vs. 5515 (3980—6218) l−1,
= 0.068, respectively] between these two groups
Fig. 1B and C). In this study, the normal range
f CRP level and WBC in men and women
as set as 0.05—0.5mg/dl, 3500—9700l−1, and
500—9300l−1, respectively. Next, we examined
L-6 and PIIINP concentrations. Here, normal ranges
f IL-6 and PIIINP levels were 0.17—9.96 pg/ml
nd 0.6—1.0U/ml, respectively. There was a sig-
iﬁcant difference in IL-6 level [median (25—75th
ercentile), 1.58 (1.09—1.97) vs. 0.99 (0.65—1.84)
g/ml, P < 0.05] between the non-valvular AF
nd the control groups, but not in PIIINP level
median (25—75th percentile), 0.7 (0.6—0.7) vs. 0.6
0.6—0.7) U/ml, P = 0.75] (Fig. 1D and E).
orrelation between TLR2 levels and
RP/IL-6 levels
e examined the statistical correlation between
LR2 level and CRP/IL-6 level of individual non-
alvular AF patients (n = 48) enrolled in this study.
LR2 levels did not correlate with CRP levels
r =−0.026, P = 0.09). Hence, TLR2 levels on mono-
ytes might serve as a new biological marker of
nﬂammation independent of CRP levels. Next, the
orrelation between TLR2 levels and IL-6 levels was
xamined (Fig. 2B). Contrary to the ﬁndings shown
n Fig. 2A, TLR2 levels were well correlated with
L-6 levels (r = 0.54, P < 0.001) in the AF patients.
ollow-up data on TLR2, IL-6 levels, and LA
olume index
ll patients in the non-valvular AF group were
reated with radiofrequency catheter ablation
o attempt to achieve complete four pulmonary
ein isolation. Therefore, the left atrial diameter
f all patients with non-valvular AF in this study
as less than 45mm. As a consequence, the
verall LAVI of patients enrolled in this study was
c
s
a
n
[atient (B). Number of patients (n), index of correlation
r) and P-value (P) are indicated in the correlation charts.
ots represent individual cases.
elatively small [median (25—75th percentile),
3.4 (29.5—38.2) ml/m2]. We carried out catheter
blation for these patients with non-valvular AF.
ne month later, 44 out of 48 patients were
onﬁrmed to be successful in the treatment, and
hen the LAVI was assessed. As shown in Fig. 3A,
he LAVI observed before ablation was signiﬁ-
antly reduced 1 month after ablation [median
25—75th percentile), 33.6 (29.6—38.2) vs. 29.5
24.0—35.0) ml/m2, P < 0.001]. As for 4 patients
ith recurrence of AF, the individual LAVI did not
hange before and after ablation. In contrast, as
hown in Fig. 3B and C, the TLR2 expression levels
nd IL-6 levels observed before ablation were
ot signiﬁcantly altered 1 month after ablation
median (25—75th percentile), 4698 (4144—5302)
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Figure 3 Comparison of the LAVI, TLR2 level, and IL-6
level in the patients judged as successful pulmonary vein
isolation (n = 44) before and after ablation. Circles con-
nected by a line show the LAVI in the same individual
before and after ablation (A). Circles connected by a line
show the TLR2 level in the same individual before and
after ablation (B). Circles connected by a line show the
IL-6 level in the same individual before and after ablation
(C). Box plot and the horizontal bar show the interquar-
tile range and median value, respectively. The whiskers
extend to at most 1.5 times the box width (the interquar-
tile range) from either or both ends of the box. P-Value
estimates were based on the Wilcoxon signed-rank test.
Figure 4 Comparison of TLR2 levels in the patients
(n = 25) between monocytes from left atrium and from
peripheral. Circles connected by a line show the TLR2
levels on monocytes taken from left atrium and periph-
eral at the same time in the same individual. Box plot
and the horizontal bar show the interquartile range and
median value, respectively. The whiskers extend to at
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rom either or both ends of the box. P-Value estimates
ere based on the Wilcoxon signed-rank test.
s. 4533 (4089—4950) sites/cell, P = 0.15, median
25—75th percentile), 1.63 (1.09—1.97) vs. 1.58
0.95—1.94) pg/ml, P = 0.43, respectively]. More-
ver, compared to before ablation CRP, WBC, and
IIINP levels did not change 1 month after ablation
mean± S.D., 0.11± 0.11 vs. 0.10± 0.09mg/dl,
= 0.26, median (25—75th percentile), 4620
3793—5308) vs. 4765 (3975—5403)l−1, P = 0.48,
.7 (0.6—0.7) vs. 0.6 (0.6—0.7) U/ml, P = 0.06,
espectively]. These results are summarized in
able 2.
omparison in TLR2 levels between two
amples from left atrium and from
eripheral
everal studies reported that some cytokines are
apable of up-regulating TLR2 expression on mono-
ytes [17,18]. Simultaneously, the secretion of
hese cytokines from inﬂammatory tissue will prime
onocyte chemotaxis. We hypothesized that blood
ampling site may be near to the focus of inﬂam-
ation in accordance with the level of up-regulated
LR2 expression. So, we examined the difference in
LR2 level between paired samples collected at the
ame time from left atrium and from peripheral.
he result is shown in Fig. 4. TLR2 level on mono-
ytes from left atrium was signiﬁcantly higher than
hat from peripheral [median (25—75th percentile),
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Table 2 Follow-up study of patients with non-valvular AF (successful PV isolation, n = 44).
Before ablation One month after ablation P-Value
WBC (l−1) 4620 (3793—5308) 4785 (3975—5403) 0.48
CRP (mg/dl) 0.11± 0.11 0.10± 0.09 0.26
TLR2 (sites/cell) 4698 (4144—5302) 4533 (4089—4950) 0.15
IL-6 (pg/ml) 1.63 (1.09—1.97) 1.58 (0.95—1.94) 0.43
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ePIIINP (U/ml) 0.7 (0.6—0.7)
LAVI (ml/m2) 33.6 (29.6—38.2)
581 (4247—5782) vs. 4216 (3728—5225) sites/cell,
< 0.01].
iscussion
ecently, we reported up-regulation of TLR2
xpression levels on monocytes in infectious inﬂam-
atory diseases including viral infections, but not
n non-infectious inﬂammatory diseases [14,15]. In
he present study, we showed that non-valvular AF
atients had higher TLR2 levels on monocytes and
L-6 levels than control patients in sinus rhythm. In
ddition, we showed that there was no signiﬁcant
ifference in CRP and PIIINP levels in ablation-
ndicated AF patients compared to control patients.
ubsequently, in 44 patients with non-valvular AF in
hom pulmonary vein isolation was conﬁrmed to be
uccessful, TLR2 and IL-6 levels were also higher 1
onth after ablation, whereas the LAVI was signiﬁ-
antly decreased.
Frustaci et al. previously documented that
bnormal atrial histology and inﬂammation was
bserved in endomyocardial biopsy specimens in all
atients with non-valvular AF, whereas biopsy spec-
mens in all patients with Wolff—Parkinson—White
yndrome were normal. The type of abnormality
aried: hypertrophy with vascular degeneration of
he atrial myocytes, lymphomononuclear inﬁltra-
ion with necrosis of the adjacent myocytes, and
onspeciﬁc patchy ﬁbrosis [19]. In addition, it has
een reported that several anti-inﬂammatory and
nti-oxidant agents have favorable effects in some
ypes of AF [20—23]. Hence, an inﬂammation is
ikely to be cited as a cause for the pathogenesis
f non-valvular AF.
Although there is consistent evidence that
nﬂammation occurs in the atrium of non-valvular
nd paroxysmal/persistent AF patients, the ele-
ation of inﬂammatory markers, such as CRP and
L-6 levels, in non-valvular AF is controversial. Elli-
or et al. reported that there was no signiﬁcant
ifference in high sensitivity (hs)-CRP between non-
alvular AF patients and controls [6]. Gedikli et
m
p
[
o0.6 (0.6—0.7) 0.06
29.5 (24.0—35.0) <0.001
l. also found that there was no signiﬁcant differ-
nce in hs-CRP and IL-6 between non-valvular AF
atients and controls [7]. In contrast, Chung et al.
howed that lone atrial tachyarrhythmia patients
ad higher CRP than controls [3], and Hatzinikolau-
otsakou et al. reported that the ﬁrst paroxysmal
pisode of non-valvular AF is associated with ele-
ated hs-CRP levels [4]. They suggested that hs-CRP
ay be a marker for inﬂammatory states that may
romote perpetuation and/or initiation of non-
alvular AF. Although our study was carried out
n non-valvular AF patients indicated for ablation
left atrial diameter <45mm), a statistically signif-
cant elevation of IL-6 levels was found in the AF
roup compared to the control group, but not CRP
evels.
Our study is the ﬁrst to demonstrate that
atients with non-valvular AF have higher TLR2
xpression levels compared to control patients.
s for the medications in this study (Table 1),
here was no statistical difference in each ratio
f patients taking these drugs between the non-
alvular AF and control groups. ACE-I, ARB,
nd statin, which are characterized as anti-
nﬂammatory drugs [24], bring about depression of
LR2 expression levels [25—27]. Considering that
atients taking medications in the non-valvular AF
roup are more than those in control group, these
rugs seem not to cause the difference in TLR2 and
L-6 levels between these two groups.In our study,
RP level was not likely to reﬂect inﬂammation
n the atrium of AF patients, and therefore it is
elieved that this gives some information about the
haracteristic of the inﬂammation. Myocarditis is
ost often induced by cardiotropic viruses and the
linical features are heterogeneous. Progression of
yocarditis to its sequela, dilated cardiomyopathy
DCM), has been documented in 20% of cases and
s pathogenically linked to chronic inﬂammation
nd viral persistence [28]. Interestingly, Sekiguchi
t al. reported atrial myocarditis-like features in
acrophage-inﬁltrated atrial endocardium during
rogression of paroxysmal/persistent AF in humans
1]. Our previous studies indicated that TLR2 level
n monocytes has a characteristic to up-regulate
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in some phases of bacterial infectious diseases
and in viral infectious diseases, but not in non-
infectious inﬂammatory diseases in the absence of
any infectious complications. In particular, TLR2
expression level seems to be more sensitive to viral
infections than CRP level [14,15]. We speculate
that this is why TLR2 levels were signiﬁcantly up-
regulated in non-valvular AF patients, but not CRP
levels.
As far as a result shown in Fig. 1, the possibility
that the inﬂammation originates not from intracar-
dia but from extracardia in non-valvular AF patients
remains. Some cytokines will be secreted from
inﬂammatory tissue, and prime the chemotaxis of
monocytes. Therefore, we speculated that blood
sampling site may be near to the focus of inﬂamma-
tion in accordance with the level of up-regulated
TLR2 expression, and examined the difference in
TLR2 level between paired samples from left atrium
and peripheral in 25 non-valvular AF patients. The
result demonstrated that TLR2 levels on mono-
cyte from left atrium were signiﬁcantly higher than
those from peripheral (Fig. 4). Taken together, it is
most likely that the focus of inﬂammation in non-
valvular AF may be intracardia.
Alternatively, the LAVI signiﬁcantly decreased
1 month after ablation in the patients judged
as successful pulmonary vein isolation. Tops et
al. previously reported a similar result [29]. In
contrast, TLR2 expression levels and IL-6 levels
remained elevated 1 month after ablation in the
present study. Also, WBC, CRP, and PIIINP levels
did not change. Consequently, we could not ﬁnd
any serological/biological marker to signiﬁcantly
change after ablation. Radiofrequency catheter
ablation is a curative procedure that attempts to
achieve complete four pulmonary vein isolation.
This mechanical procedure is unlikely to suppress
inﬂammation and the associated markers. The sig-
niﬁcant reduction of LAVI may be associated with
the reverse remodeling of atrium due to alleviation
of AF rather than the resolution of inﬂammation.
It is a limitation to examine the recurrence of AF
in this study. Relapsed AF patients were too small
to be statistically analyzed. Further study including
a large number of refractory AF patients will be
required.
In the present study, we examined the differ-
ences in serological/biological markers between
the non-valvular AF and control groups. The result
showed that TLR2 expression levels and IL-6 lev-
els were signiﬁcantly higher in non-valvular AF
patients than in control patients. Subsequently, it
was demonstrated that TLR2 levels were moder-
ately correlated with IL-6 levels, but not with CRP
levels. Furthermore, although the TLR2 expression
[H. Ichiki et al.
evels and IL-6 levels in non-valvular AF remained
levated 1 month after successful ablation, it was
emonstrated that the LAVI signiﬁcantly dimin-
shed. In conclusion, our results suggest that an
nfectious inﬂammation, characterized by TLR2 up-
egulation on monocytes, may participate in the
athogenesis of non-valvular AF.
cknowledgments
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